PharmaResearch Co., Ltd. (KOSDAQ:214450)

South Korea · Delayed Price · Currency is KRW

413,500

+22,500 (5.75%)

Aug 20, 2026, 3:30 PM KST

-38.74% (1Y)

Market Cap	4.30T -38.1%
Revenue (ttm)	565.48B +44.1%
Net Income	176.52B +59.1%
EPS	15,890.22 +49.2%
Shares Out	10.39M
PE Ratio	26.02
Forward PE	25.03
Dividend	3,700.00 (0.95%)
Ex-Dividend Date	Dec 29, 2025

Volume	158,339
Open	398,500
Previous Close	391,000
Day's Range	398,500 - 416,500
52-Week Range	255,000 - 713,000
Beta	0.45
Analysts	Buy
Price Target	508,357.14 (+22.94%)
Earnings Date	Aug 7, 2026

About PharmaResearch

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults thro... [Read more]

Industry Medical - Pharmaceuticals

Sector Healthcare

Founded 1993

Employees 542

Stock Exchange KOSDAQ

Ticker Symbol 214450

Full Company Profile

Financial Performance

In 2025, PharmaResearch's revenue was 536.29 billion, an increase of 53.18% compared to the previous year's 350.12 billion. Earnings were 165.12 billion, an increase of 79.39%.

Financial Statements

Analyst Summary

According to 14 analysts, the average rating for 214450 stock is "Buy." The 12-month stock price target is ₩508,357, which is an increase of 22.94% from the latest price.

Price Target

₩508,357

(22.94% upside)

Analyst Consensus: Buy

Stock Forecasts